vs
ARCBEST CORP（ARCB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ARCBEST CORP的季度营收约是Revvity的1.3倍（$998.8M vs $772.1M），Revvity净利率更高（12.7% vs -0.1%，领先12.8%），Revvity同比增速更快（5.9% vs 3.3%），过去两年Revvity的营收复合增速更高（9.0% vs -3.7%）
ArcBest是美国头部物流与运输解决方案提供商，提供零担货运、整车运输、仓储、加急配送及定制化物流咨询等全链路供应链服务，覆盖北美及全球部分市场，服务对象包含企业、小型商家及公共部门客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ARCB vs RVTY — 直观对比
营收规模更大
ARCB
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出2.6%
3.3%
净利率更高
RVTY
高出12.8%
-0.1%
两年增速更快
RVTY
近两年复合增速
-3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $998.8M | $772.1M |
| 净利润 | $-1.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 0.3% | 14.5% |
| 净利率 | -0.1% | 12.7% |
| 营收同比 | 3.3% | 5.9% |
| 净利润同比 | -133.1% | 3.9% |
| 每股收益（稀释后） | $-0.05 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARCBRVTY
| Q1 26 | $998.8M | — | ||
| Q4 25 | $972.7M | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $967.1M | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润ARCBRVTY
| Q1 26 | $-1.0M | — | ||
| Q4 25 | $-8.1M | $98.4M | ||
| Q3 25 | $39.3M | $46.7M | ||
| Q2 25 | $25.8M | $53.9M | ||
| Q1 25 | $3.1M | $42.2M | ||
| Q4 24 | $29.0M | $94.6M | ||
| Q3 24 | $100.3M | $94.4M | ||
| Q2 24 | $46.9M | $55.4M |
毛利率ARCBRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ARCBRVTY
| Q1 26 | 0.3% | — | ||
| Q4 25 | -0.8% | 14.5% | ||
| Q3 25 | 5.2% | 11.7% | ||
| Q2 25 | 3.6% | 12.6% | ||
| Q1 25 | 0.7% | 10.9% | ||
| Q4 24 | 3.8% | 16.3% | ||
| Q3 24 | 12.7% | 14.3% | ||
| Q2 24 | 4.5% | 12.4% |
净利率ARCBRVTY
| Q1 26 | -0.1% | — | ||
| Q4 25 | -0.8% | 12.7% | ||
| Q3 25 | 3.7% | 6.7% | ||
| Q2 25 | 2.5% | 7.5% | ||
| Q1 25 | 0.3% | 6.4% | ||
| Q4 24 | 2.9% | 13.0% | ||
| Q3 24 | 9.4% | 13.8% | ||
| Q2 24 | 4.4% | 8.0% |
每股收益（稀释后）ARCBRVTY
| Q1 26 | $-0.05 | — | ||
| Q4 25 | $-0.35 | $0.86 | ||
| Q3 25 | $1.72 | $0.40 | ||
| Q2 25 | $1.12 | $0.46 | ||
| Q1 25 | $0.13 | $0.35 | ||
| Q4 24 | $1.21 | $0.77 | ||
| Q3 24 | $4.23 | $0.77 | ||
| Q2 24 | $1.96 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $86.4M | $919.9M |
| 总债务越低越好 | $223.7M | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $2.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资ARCBRVTY
| Q1 26 | $86.4M | — | ||
| Q4 25 | $124.2M | $919.9M | ||
| Q3 25 | $132.6M | $931.4M | ||
| Q2 25 | $139.7M | $991.8M | ||
| Q1 25 | $98.7M | $1.1B | ||
| Q4 24 | $157.2M | $1.2B | ||
| Q3 24 | $191.1M | $1.2B | ||
| Q2 24 | $260.5M | $2.0B |
总债务ARCBRVTY
| Q1 26 | $223.7M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $214.1M | — | ||
| Q2 25 | $241.4M | — | ||
| Q1 25 | $214.2M | — | ||
| Q4 24 | $189.1M | — | ||
| Q3 24 | $180.5M | — | ||
| Q2 24 | $203.6M | — |
股东权益ARCBRVTY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B |
总资产ARCBRVTY
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B |
负债/权益比ARCBRVTY
| Q1 26 | 0.17× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ARCBRVTY
| Q1 26 | — | — | ||
| Q4 25 | $44.7M | $182.0M | ||
| Q3 25 | $98.2M | $138.5M | ||
| Q2 25 | $108.4M | $134.3M | ||
| Q1 25 | $-22.3M | $128.2M | ||
| Q4 24 | $56.8M | $174.2M | ||
| Q3 24 | $88.8M | $147.9M | ||
| Q2 24 | $133.7M | $158.6M |
自由现金流ARCBRVTY
| Q1 26 | — | — | ||
| Q4 25 | $36.9M | $161.8M | ||
| Q3 25 | $33.2M | $120.0M | ||
| Q2 25 | $80.9M | $115.5M | ||
| Q1 25 | $-36.8M | $112.2M | ||
| Q4 24 | $3.5M | $149.8M | ||
| Q3 24 | $23.9M | $125.6M | ||
| Q2 24 | $83.9M | $136.6M |
自由现金流率ARCBRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 21.0% | ||
| Q3 25 | 3.2% | 17.2% | ||
| Q2 25 | 7.9% | 16.0% | ||
| Q1 25 | -3.8% | 16.9% | ||
| Q4 24 | 0.4% | 20.5% | ||
| Q3 24 | 2.2% | 18.4% | ||
| Q2 24 | 7.8% | 19.7% |
资本支出强度ARCBRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 6.2% | 2.6% | ||
| Q2 25 | 2.7% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 5.3% | 3.4% | ||
| Q3 24 | 6.1% | 3.3% | ||
| Q2 24 | 4.6% | 3.2% |
现金转化率ARCBRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.50× | 2.97× | ||
| Q2 25 | 4.20× | 2.49× | ||
| Q1 25 | -7.13× | 3.03× | ||
| Q4 24 | 1.96× | 1.84× | ||
| Q3 24 | 0.89× | 1.57× | ||
| Q2 24 | 2.85× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARCB
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
